Charles River White Paper: CAR-T IND Success

CAR-T cell therapies are exciting therapeutic modalities that have garnered substantial success in the clinic, particularly for certain disseminated cancers. As the field improves, insights from late-stage successes (and failures) are being fed back into early antibody discovery research and antibody engineering paradigms for these valuable constructs to increase success rates for CAR-T developers.

To learn more complete the form and download our free whitepaper.